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Circadian Variation of Ventricular Arrhythmias is
of Importance for Effective Drug Therapy
Thomas S. Faber. Manfred Zehender. Martin Baumgarten. Andreas Jeron,
Armin Furtwangler. Hanjorg Just. Universitiitsklinik Fre/burg, Innere Medizin 11/.
Germany
With regard to the restrictive and safe use of class I-antiarrhythmics (AA)
clinical criteria predicting drug efficacy and safety have become important.
In 140 pts (102 men. 63 ± 7 years) with frequent and symptomatic. but
not life-threatening arrhythmias (VA; >30fh) occurrence. reproducibility and
therapeutic consequences of a circadian distribution (CD) of single/repetitive
VA was studied. Pts underwent 3 24 h-Holter recordings at baseline. after 2
weeks of placebo and after 6 weeks of dose-titrated antiarrhythmic therapy.
67/140 pts (48%) had reproducible day-night CD (daytime VA increase: 50/67
pts. 75%). In Cox's regression analysis CD was characteristic of a lower VA
rate (p < 0.05), but more frequent tachycardia episodes (risk: 3.8 times. p <
0.05) and a lower ejection fraction. AA response was better in pts with CD
(3.3 times. p < 005). Day-/night CD pattern was also predictive for a superior
response of class IA or IC agents (Fig.).
three times daily. In each case tilt test was negative after 6 weeks treatment
and they all remained free of symptom during a follow up of 6 ± 1 months.
Only 3 of the 8 patients in group B with positive tilt testing at the 6th week
were controlled with metoprolol. The circulating catecholamines levels at
baseline and during tilt testing were not significantly different between pa-
tients successfully treated by metoprolol or disopyramide. The changes of
the neurohormones were not different during disopyramide and metoprolol
treatments. We conclude that 100 mg daily metoprolol is significantly less
efficient than disopyramide 300 mg daily in the long term treatment of recur-
rent neurocardiogenic syncope.
In conclusion. CD of VA is common in half of the pts with symptomatic VA.
When class I agents are used. CD provides clinical evidence for selection of
the most effective AA and dose and may help to improve overall antiarrhyth-
mic benefit.
'p < 0.05 vs C, "p < 0.01 vs C,D,P
Either after P or D + P heart rate resulted lower than control not only at
Aim olthe study was to evaluate the effect of digoxin (D) in combination with
propafenone (P) on the ventricular rate during stable atrial fibrillation (AF).
We evaluated 15 patients (pts.) (age 57 ± 9 years. NYHA :::: 2) with stable AF
during effort by cycloergometer in a randomized study with four phases: 1)
no treatment, for control (C). 2) in steady state treatment with oral digoxin (D)
at at 0 125--0.375 mg/die according to serum digoxin levels (0.8-1 .8 ng/ml).
3) three hours after oral loading with propafenone (P) at 600 mg. and 4) three
hours after oral loading with propafenone while assuming oral digoxin (D +
Pl. The sequence of C. D, P and D + P phases was randomised and the
exercise tests were performed every 7-10 days at the same. Resu/ts:
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Metoprolol Versus Disopyramide in the
Management of Recurrent Neurocardiogenic
Syncope
Emile G. Daoud, Mark J. Niebauer, K. Ching Man. S. Adam Strickberger,
William Kou, Fred Morady. Veteran Affairs Medical Center and University of Michigan
Hospital. Ann Arbor, MI
In retrospective studies. quinidine-induced proarrhythmia and excessive
lengthening of the OT inteNal have been described to occur in 5-10% of
patients (pts). There are, however. no prospective studies. Therefore, the pur-
pose of this study was to prospectively assess the acute effects of quinidine
on the OT interval and on the incidence of proarrhythmic events in hospi-
talized pts. using daily 12-lead ECG's and continuous telemetric monitoring.
Clinical data included gender. age. body surface area, left ventricular ejec-
tion fraction (LVEF), etiology of heart disease, congestive heart failure class,
O-wave infarction pattern, indication for quinidine. quinidine and potassium
serum levels. and use of a diuretic. digoxin or an antiarrhythmic agent. Pts
were followed until time of discharge. Ouinidine was initiated in 35 pts (18
M; 17 F) for supraventricular (n ~ 221 or ventricular (n = 13) arrhythmias 19
pts had an ischemic, 6 had a non ischemic, and 3 had a valvular cardiomyopa-
thy; 5 had hypertensive and 2 had no heart disease. The mean age was 63
± 13 years. the mean LVEF was 0.38 ± 0.15 and the mean functional class
was 2.0 ± 1.1. The mean quinidine level was 2.7 ± 1.2 iL9/ml.
The OT interval increased from 388 ± 61 to 499 ± 70 msec (p < 0.01) and
the OTc increased from 445 ± 61 to 543 ± 60 rnsec (p < 0.005). 11 pts (31 %)
developed a OTc > 550 msec. Torsade de pointes In = 3) or other ventricular
proarrhythmic events (n = 3) occurred in 6 pts (17%). The pts experiencing
torsade de pointes were female pts with a mean LVEF of 0.24 and a OTc of
610 to 650 msec. Female gender (p = 005). younger age (p ~ 0.04). lower
LVEF Ip = 0.01). and an increased baseline OTc inteNai (p < 0.005) were
statistically associated with proarrhythmia. Proarrhythmic events occurred
on day 23 ± 1 of quinidine therapy (range: 1-41.
In conclusion. in this prospective study of hospitalized pts. quinidine re-
sulted in lengthening of the OTc inteNal beyond 550 rnsec in 31 % of the
pts and in a 17% incidence of clinically significant ventricular proarrhythmia.
Proarrhythmia was statistically associated with female gender. decreased
LVEF and increased baseline OTc inteNal. The results of this prospective
study indicate that the incidence of quinidine-induced proarrhythmia and ex-
cessive OT prolongation may be higher than the 5-1 0% incidence previously
reported in retrospective studies.
phases of sustained (2:1 min) atrial flutter or atrial tachycardia; in these ar-
rhythmia after PFN AV conduction ratio was 2; 1 in 2 cases (ventricular rate
115-140/minl and 2:3: 1 in the others (ventricular rate 60--95/min) while af-
ter PLA AV conduction was 1: 1 in 1 case (ventricular rate 240/min), 2: 1 in 3
cases (ventricular rate 120-150/min) and 2:3: 1 in the others (ventricular rate
60-100/min). Pauses> 2 s occurred in 1 case after PFN and in 3 after PLA.
Moreover after PFN slight hypotension occurred in 5 patients, together with
bradycardia in 3 cases, and ORS enlargement to more than 0.12 s was ob-
seNed in 3 cases. In conclusion oral loading with PFN is a very effective reg-
imen for converting recent-onset AF to SR. Because of its favourable safety
profile, its employement, under clinical control. in selected patients without
left ventricular dysfunction or heart failure. is advisable. Finally, in patients
with recent-onset AF phases of atrial flutter or atrial tachycardia may occur
not only after PFN but even after PLA.
Prospective Assessment of Quinidine-induced QT
Prolongation and Proarrhythmia in Hospitalized
Patients
We evaluate the efficiency of 50 mg oral metoprolol twice daily as compared
to 100 rng oral Disopyramide three-time daily for the treatment of recur-
rent neurocardiogenic syncope. Seventy patients were reffered to our center
since January 1992, for the diagnosis of vasovagal syncope. In 19 cases the
syncope was finally related to a cardiac or neurologic cause. Fifty one pa-
tients (73%) had bradycardia or asystole during tilt testing (70 degrees for
less than 20 minutes without isoproterenol infusion). These patients were
treated by either 50 mg metoprolol twice daily (group A, n = 251 or 100 mg
disopyramide three-times daily (group B. n = 25). Evaluation consisted on
tilt testing 6 weeks after onset of treatment and clinical evaluation one year
after. In case of positive tilt testing 6 weeks after treatment, the patient re-
ceived the opposite treatment and was evaluated again 6 weeks after. Seven
of group A 128%) had a negative controlled tilt test 6 weeks after treatment
onset versus 17 patients in group B (68%. p = 0002). Only 6 patients (24%)
in group A remained asymptomatic during a follow up of 12 ± 2 months
versus 15 patients in group B (60%, p = 0.001). The 18 patients in group A
having a positive tilt test at the 6th week, received 100 mg oral disopyramide
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peak exercise but also at the second and fourth minute of effort (p < 0.03
and p < 0.01, respectively) resulting in a more gradual HR increase during
the first phases of effort. No major side effect occurred.
In conclusion in pts. with stable AF propafenone is able to achieve a sig-
nificant control of HR increase during effort, probably by virtue of its slight
beta-blocking effect. Moreover the combination of D + P results in an addi-
tive effect with a better control of HR during effort.
Continuous Infusion of Prostacyclln (PGIz)
Improves Survival in Severe Pulmonary
Hypertension
A. Yazdani Butt, George Cremona, Linda Sharples, Tim W. Higenbottam. Papworth
Hospital Cambridge, England, UK
In primary pulmonary hypertension PGI2, when added to conventional ther-
apy, enhances early survival at 3 months and improves exercise tolerance
(Long et ai, Am Rev Respir Dis 1993; 149: A538). High dose Ca++ channel
blockers may improve survival in mild to moderate disease (Rich et ai, N Eng
J Med 1992; 327: 76-81). We have compared the effect of continuous infu-
sion of PGI2 on survival of 114 patients with pulmonary hypertetion where
severity of disease was determined by a mixed venous oxygen saturation
(Sv02)' Patients were categorized into groupl ISv02 2: 60%) and group2
(Sv02 < 60%) at diagnostic right heart catheterization. Majority of patients
had primary pulmonary hypertension In = 90) while others had thromboem-
bolic disease (n = 24). 67 patient were treated with PGI2, while 47 patients
were treated with conventional therapy (CT) ie. anticoagulants with or with-
out oral vasodilators. End point of the study was either death or heart-lung
transplantation.
tration. In conclusion, BPS could provide a favorable remedy in the treatment
of patients with PH.
Diuretic Therapy Improves Exercise Capacity in
Patients with Angina but has no Effect on Nitrate
Tolerance
John D. Parker, Andrea B. Parker, Bernice Farrel, John O. Parker. Kingston General
Hospital, Kingston, and Mount Sinai Hospital, Toronto, Ontario, Canada
Diuretics have been reported to prevent tolerance to the organic nitrates.
Since diuretic therapy itself may have an anti-anginal effect, we carried out
a study which examines the effect of diuretic therapy alone on exercise ca-
pacity in angina as well as its effect on nitrate tolerance.
Methods. 12 patients with stable angina were studied. All had normal LV
systolic function. None were hypertensive or had a history of CHE Patients
received a diuretic (HCTZ plus amiloride) or placebo for 10-14 days in a ran-
domized, double-blind, cross-over trial. During the last 5-7 days of each treat-
ment period they received continuous transdermal nitroglycerin (TGTN) 0.8
mglhr in a single blind manner. Treadmill walking time (TWTl was assessed
prior to the addition of TGTN (Day 1) to assess the effect of diuretic alone,
on the first day of TGTN therapy (Day 2) and on the last day of TGTN therapy
(Day 3). Exercise testing was performed at 0800, 1200 and 1600 hrs on each
of these days.
Results. Diuretic therapy caused an increase in TWT on all 3 study days.
HR and systolic BP were higher at peak exercise during diuretic therapy as
compared to placebo (data not shown). Diuretic therapy did not prevent the
development of tolerance during continuous TGTN therapy.
Mean (Inter-quartile rangel. *P < 0.05, Likelihood ratio test
Continuous PGl2 infusion, in comparison to CT, improved median survival
in patients with severe pulmonary hypertension who had Sv02 of less than
60%. However in moderate disease with Sv02 of 2: 60%, PGl2 had no ad-
vantage over CT. Continuous long term PGl2 may be a useful treatment in
selected patients with pulmonary hypertension where Sv02 is less than 60
percent.
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*p = < 0.05 vs placebo (cross over analysis of Hills and Armitage).
Conclusions. Diuretic therapy has significant anti-anginal effects and im-
proves exercise capacity in patients with stable angina. Diuretics appear to
have no effect on the development of tolerance to continuous TGTN therapy
as assessed by treadmill exercise testing.
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Yasunori Nakayama, Yoshiaki Okano, Toru Satoh, Akito Shimouchi,
Takeyoshi Kunieda. Division of Cardiology, Department of Internal Medicine, National
Cardiovascular Center, Suita, Osaka. Japan
Intravenous infusion of prostacyclin (PGI2) is considered to be one of the
most effective vasodilating remedy in patients with pulmonary hypertension
(PH). To determine whether beraprost sodium (BPS), a oral PGI2 derivative,
clinically available in Japan, is also effective in PH. We selected 11 patients
(3 males, 8 females, 42 ± 13 years old) with moderate to severe PH (NYHA
II I'" IV) dueto primary or inoperable thromboembolic PH. Hemodynamic mea-
surements by means of cardiac catheterization were performed before and
immediately after single dose of oral BPS (60-100 JLg). and restudied after 1
to 2 months of chronic administration (20-40 JLg, t.i.d.l.
Results: (1) Acute effects; There were significant decrease in mean pul-
monary artery pressure (PAm) (70 ± 13-+55 ± 12 mmHg, p < 0.01) and total
pulmonary resistance (TPR) (19.9 ± 10.6-+ 16.8 ± 11.7 u, p < 0.05). and in-
crease in cardiac output (CO) (3.0 ± 1.1-+3.5 ± 1.7 I/min, p < 0.05) at the
maximum effects. TPR decreased more than 20% in 5 of 11 patients. There
were also slight but not significant decrease in mean systemic blood pres-
sure (SAm)(81 ± 10to 73 ± 4 mmHg)taken as a whole, but obviously fell in 3
patients more than 30%. (2) Chronic effects; PAm (47.5 ± 7 mmHg) and TPR
(14.1 ± 3.4 u) significantly decreased, and CO (3.5 ± 0.8I/min) significantly
increased compared with baseline values. TPR decreased more than 20%
in all but one patient. SAm (81 ± 8 mmHg) were not significantly reduced,
and did not fall more than 20% in any patient. All patients are alive and in
better conditions during 12.1 ± 6.1 months follow up with chronic adminis-
Survival After Large Myocardial Infarction in Rats:
Comparison of ACE Inhibition with Captopril
Versus Direct Angiotensin 1\ Blockade with
Losartan
James J. Milavetz, Thomas E. Raya, Eugene Markin, Steven Goldman. Veterans
Administration Medical Center and University ofArizona Heart Center, Tucson, AZ
To compare the effects of angiotensin converting enzyme (ACE) inhibition
vs angiotensin II (A-II) receptor blockade on survival, rats with large myocar-
dial infarctions were treated with captopril (N = 46) or losartan (N = 51) a
specific A-II antagonist, at a dose of 2 gIL drinking water. Therapy was initi-
ated immediately after coronary artery ligation and continued for one year.
Median survival in captopril treated rats was 191.4 ± 14.1 days vs 246.4 ±
15.7 days for losartan treated rats (P < 0.03). Measurements of myocardial
function and LV geometry were obtained at one year in surviving rats (N =
5 for captopril; 9 for losartan). No differences were noted in heart weight,
LV pressures, dPldt, cardiac index, time constant of relaxation, or LV volume
and dimensions. In losartan-treated rats, however, heart rate was increased
1293 ± 19 vs 266 ± 15 beatslmin, P < 0.05) and peak developed pressure
was decreased (153 ± 21 vs 180 ± 16 mmHg, P < 0.05). Thus, in the rat
model of heart failure, survival was prolonged with losartan compared to
captopril, suggesting that the major benefit of ACE inhibition is attenuation
of responses mediated through the A-II receptor.
